SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes

Shanghai Jiao Tong University

Status: Not yet enrolling

Conditions: Lung Cancer

Treatments: Drug: SGLT-2 inhibitor; Other: Sham (No Treatment)

Study type: Interventional

Funder types: Other

Identifiers

NCT07272057

SLC-DO

Details and patient eligibility

About

The goal of this clinical trial

The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and diabetes. It will also check if these drugs are safe for these patients. The main questions it aims to answer are:

• Does adding an SGLT2 inhibitor to standard cancer treatment improve survival?
• Does it cause more or fewer cardiovascular toxicity?
• What side effects do participants experience? Researchers will compare a group taking an SGLT2 inhibitor to a group not taking SGLT2 inhibitor to see if the drug works.

Participants will:

• Be adults diagnosed with advanced lung cancer and type 2 diabetes.
• Take either the SGLT2 inhibitor pill or other hypoglycemic drugs once a day alongside their cancer treatment.
• Undergo regular clinical visits for monitoring, laboratory tests, and imaging studies

Enrollment: 200 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lung cancer patients receiving standard anti-tumor treatment; type 2 diabetes; patients with a score of 0-2 assessed by Eastern Cooperative Oncology Group's performance status; the patients agreed to participate in this study.

Exclusion criteria

• Severe abnormalities in liver, kidney or heart functions; expected lifespan less than 3 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

200 participants in 2 patient groups

treatment group

Experimental group

Description:

On the basis of standard cancer treatment, take dapagliflozin for at least three months, once a day, 10 mg each time.

Treatment:

Drug: SGLT-2 inhibitor

control group

Sham Comparator group

Description:

Based on the standard treatment for tumors, for the treatment of diabetes, no dapagliflozin has been taken.

Treatment:

Other: Sham (No Treatment)